The PIONEER-HF trial demonstrated in-hospital initiation of sacubitril/valsartan to be safe and to be associated with a significant reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and HF rehospitalizations compared with enalapril [11, 12]. The gene discussed is NPPB; the disease is hydrops fetalis.